Download Drug design / 9 by E J Ariens PDF
By E J Ariens
Read Online or Download Drug design / 9 PDF
Best industrial & technical books
Multivariate Datenanalyse GERMAN
In vielen Fachgebieten, wie z. B. der Lebensmittelchemie, der pharmazeutischen oder biotechnologischen Industrie fallen immer mehr Daten an, die ausgewertet werden m? ssen. Klassische Verfahren gelangen hierbei schnell an ihre Grenzen. Die multivariate Datenanalyse besch? ftigt sich mit Verfahren, mit denen guy aus einer F?
Content material: Enzymes for fuels and chemical feedstocks / okay. Grohmann and Michael E. Himmel -- Enzymes in pulp and paper processing / L. Viikari, A. Kantelinen, M. Rättö, and J. Sundquist -- Enzymes for anaerobic municipal sturdy waste disposal / Christopher J. Rivard, William S. Adney, and Michael E. Himmel -- Thermostable saccharidases : new assets, makes use of, and biodesigns / J.
- The Chemistry and Physics of Coatings
- Nanomaterials in Advanced Batteries and Supercapacitors
- Computer Methods in Chemical Engineering
- Homogeneous Gold Catalysis
- Alkyl Polyglycosides: Technology, Properties, and Applications
- Leading with Safety
Extra resources for Drug design / 9
Example text
7, p. 20. Academic Press, New York, 1976. 75. T. S. " Elsevier, Amsterdam, 1962. 76. F. Seutter-Berlage, H. L. van Dorp, H. G. J. Kosse, and P. Th. Henderson, Int. Arch. Occup. Environ. Hlth. 39, 45 (1977). 77. J. R. Sibert, A. W. Craft, and R. H. Jackson, Lancet 2, 289 (1977). 78. P. Sims and P. L. Grover, Adv. Cancer Res. 20, 165 (1974). 79. B. Singer, TIBS 2, 180 (1977). 80. A. D. Tates, T. Soc. Geneesk. 55, 140 (1977). 81. J. A. Timbrell and J. R. Mitchell, Xenobiotica 7, 415 (1977). 82. H.
I m p u r i t i e s in salicylic acid preparations k microsomal mixed function oxidase >v O ct'OH ^ ^ C - O H N ' O Co biologically acylating lacton Fig. 27. Structures with potential biological acylating action. 40 E. J. ARIENS indirectly acting d i r e c t l y act ing R - C - C - -CI YV AJL^ ^ a r y lamines ^γΝΗ II o R - N - C - -c- CI R_N \IC ethyleneamines bay region' R-C-C epoxides R-C=C-C=0 Q α-β unsaturated compounds It R-S-O-C II XJt ^ ^ " k region" polycyclic alkylalkanesulfates hydrocarbons O O R-O-S-O-C ö 2 dialkylsulfates R-C= C - C ß-lactons halogennitrobenzenes R-C= c-ci unsaturated groups ally 1, v i n y l e t c .
A more direct and thus clearer relationship between structure and activity, the basis for an optimal design of new agents, is a further advantage (4). d. Reduction in Toxicity by Metabolic Stabilization. As can be concluded from the foregoing sections, the control of drug metabolism—be it either in the sense of developing metabolically stable agents or in developing agents metabolized along controlled pathways, avoiding risky metabolic handles, and making use of safe, nontoxicogenic, metabolic handles—may reduce the toxicological risks (5, 6).